Teva collaborates on skin disease treatment, releases targets

Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while ...

XOMA Royalty Corporation: XOMA Royalty Announces CFO Transition

XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his ...

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...
The Malaysian Reserve

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –– Unaudited 2025 total product and royalty revenue of ...
Asianet Newsable on MSN

Why is TEVA stock rising pre-market today?

Teva announced a funding agreement with Royalty Pharma of up to $500 million to advance its anti-IL-15 antibody, TEV-‘408, ...

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royaltiesRoyalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple ...
Fierce Biotech

Teva lines up $500M in Royalty Pharma funding for vitiligo drug

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

Royalty Pharma Raises Quarterly Dividend by 6.8%

Royalty Pharma's board has raised the biopharmaceutical royalties investor's quarterly dividend by 6.8%, to 23.5 cents from 22 cents. The new payout, equal to 94 cents a year, represents an annual ...